

BLYTHE ADAMSON, PHD, MPH

New York, NY | 253.225.4466 | blytheadamson.com

EXPERIENCE

- Director, Quantitative Scientist** 06.2018 – Present
Flatiron Health, New York, NY
Head of Health Technology Assessment, leading team of scientists and engineers in methods and analysis of electronic health records-derived data from 2.2 million cancer patients to improve patient lives
- Founder** 08.2017 – Present
Infectious Economics, LLC, New York, NY
Independent infectious disease consultant and generator of economic evidence for development of valuable drugs, vaccines, and public health policy, Advising governments, industry, and non-profit organizations
- Advisor** 04.2020 – Present
Testing for America, Washington, DC
Expert infectious disease epidemiologist designing COVID testing protocols and programs
- Research Scientist** 2017 – 2018
Salutis Consulting, Seattle, WA
Developed a common model to evaluate the economic impact of comparative-effectiveness research to inform healthcare decision-making in the United States; applied the math model to five disease areas
- Health Economist** 2016 – 2018
Fred Hutchinson Cancer Research Center, Seattle, WA
Led cost-effectiveness analysis of SABES testing for acute HIV infections in Lima, Peru (PI: A Duerr)
- Senior Infectious Disease Economist** 2016 – 2017
Consultants in Global Health, Seattle, WA
Advising balance of costs-benefit tradeoffs for health tech in global low and middle-income markets
- Interim Global Health Research Economist** 2016 – 2017
Institute for Disease Modeling, Gates Ventures, Bellevue, WA
Designed economic demand model of healthcare services for the Bill and Melinda Gates Foundation and Center for Global Development, advising on health economics methods for infectious diseases
- Epidemiologist** 01 – 09.2016
Boston Scientific, Minneapolis, MN
Technology Road Mapping Team, forecasted global burden of disease for R&D prioritization
- Co-Founder** 2015 – 2019
SmartDx, Seattle, WA
Developed cloud-based infectious disease diagnostic platform to support clinical decision-making, leveraging real-time analytics, disease surveillance, and patient risk factors
- Research Analyst** 2015 – 2016
Global Good, Intellectual Ventures, Bellevue, WA
Synthesized evidence and identifying knowledge gaps for inventors to improve health care technologies in low-income countries as a member of the Virtual Research Analyst Network
- Project Manager** 2007 – 2014
HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA
Managed concept and protocol development; created global scientific mentoring programs awarding >40 scholars; developed 30+ trainings/workshops for clinical trial site staff

BLYTHE ADAMSON, PHD, MPH

Lab Technician 2003 – 2007
Department of Laboratory Medicine, University of Washington, Seattle, WA
Identified and analyzed escape mutations in breakthrough HIV. Lab skills: PCR, sequencing, phylogenetics

EDUCATION | TRAINING

University of Washington, Seattle WA

Doctorate, Pharmaceutical Science 2014 – 2018
Dissertation: Clinical and Economic Impact Models of Biomedical HIV Prevention Strategies in the US

Master in Public Health, Epidemiology 2008 – 2009
Master Thesis: Predictors of Immunogenicity in HIV Vaccine Clinical Trials

Bachelor in Science, Microbiology 2003 – 2006
Honors Thesis: Escape Mutations in HIV-1 Elite Suppressors

LEADERSHIP | SERVICE

Member, ISPOR Machine Learning in Health Economics Task Force 2019 – 2021

Member, ISPOR New Professionals Steering Committee 2019 – 2021

Committee Member and Reviewer, ISPOR Distance Learning Program 2017 – 2019

Global Chair, ISPOR Student Network 2017 – 2018
Led 10 committees, 123 student chapter presidents, and >5,000 graduate students in 37 countries to equip the next generation of health economics and outcomes research professionals.

Advisor, ISPOR IT Operations 2017 – 2019
Providing input on IT software, consulting, and staffing for efficiency in operations and data-driven decisions

Co-Chair, Survey and Evaluation Committee 2016 – 2017
Lading 9-member committee to develop, implement, and analyze four surveys for evaluation and action plan

President, University of Washington ISPOR Student Chapter 2016 – 2017
Led five officers in bi-weekly meetings and represented >30 chapter members

Vice President, University of Washington ISPOR Student Chapter 2015 – 2016

RESEARCH | ASSISTANTSHIPS

Principal Investigator: Aasthaa Bansal, PhD 2016 – 2017
University of Washington, Seattle, WA
Designed and developed microsimulation model in R of chronic myeloid leukemia to assess potential for treatment switching using dynamic biomarker trajectory predictions, funded by PhRMA Foundation

Principal Investigator: Helene Starks, PhD 01 – 06.2005
China Center for Disease Control, remote to Beijing, China
Qualitative data analysis of barriers to HIV treatment adherence in China

PUBLISHED | MANUSCRIPTS

1. Ramsey et al. Using Electronic Health Record Data to Identify Comparator Populations for Comparative Effectiveness Research. *Submitted*, 2020.
2. Kerrigan KC et al. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. *Submitted*, 2020.
3. Bennette C, Lyons H, Wagner B, **Adamson B**, Change S, on behalf of the IDM COVID-19 Response Team. Inequitable availability of COVID-19 clinical trials for Hispanic populations in the United States. *Institute for Disease Modeling InfoHub Pre-Print*. 19 Aug 2020.
https://covid.idmod.org/data/Inequitable_availability_COVID-19_clinical_trials.pdf

4. Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, **Adamson BJ**, Shaw P, Parikh RB, Mamtani R, Gross CP. The Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. *JCO Oncology Practice*. In Press, 2020.
 5. Castellanos EH, Orlando A, Ma X, Parikh RB, O'Connell G, Meropol NJ, Hamrick J, **Adamson BJS**. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment. *JCO Oncology Practice*. 2020 Jun 4; JOP1900747. DOI: 10.1200/JOP.19.00747.
 6. Ma X, Long L, Moon S, **Adamson BJS**, Baxi SS. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR. *MedRxiv*. medRxiv 2020.03.16.20037143; doi: <https://doi.org/10.1101/2020.03.16.20037143>
 7. Parikh RB, Feld E, Galsky M, **Adamson B**, Cohen C, Baxi S, Christodouleas J, Vaughn D, Meropol N, Mamtani R. First-line Immune Checkpoint Inhibitor Use in Cisplatin-Eligible Patients with Advanced Urothelial Carcinoma. *Future Oncology*. 16 Dec 2019. 16 (02), 4341-4345. doi: <https://doi.org/10.2217/fon-2019-0578>.
 8. Parikh RB*, **Adamson BJS***, Khozin S, Galsky MD, Baxi SS, Cohen AB, Mamtani R. Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer. *JAMA*. 2019;322(12):1209-1211. doi:10.1001/jama.2019.10650. *Co-first authors contributed equally to this study.
 9. **Adamson B**, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D. Potential competition between biomedical HIV prevention strategies in Seattle, WA. *Journal of the International AIDS Society*. 2019 Aug 10; 22(8):e25373. DOI:10.1002/jia2.25373.
 10. Feld E, Harton J, Meropol NJ, **Adamson BJS**, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R. Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. *European Urology*. 2019 Jul 27. 76(4):524-532. doi: 10.1016/j.eururo.2019.07.032. PMID: 31362898.
 11. Dimitrov D, Wood D, Ulrich A, Swan D, **Adamson BJS**, Lama J, Sanchez J, Ann Duerr D. Projected Effectiveness of HIV Detection During Early Infection and Rapid ART Initiation among MSM and Transgender Women in Peru: A Modeling Study. *Infectious Disease Modeling*. 2019 Apr 6;4:73-82. doi: 10.1016/j.idm.2019.04.001. PMID: 31025025
 12. El-Deiry WS, Winer A, Slifker M, Taylor S, **Adamson BJS**, Meropol NJ, Ross EA. Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond BOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). *Front. Oncol*. 2019, 9:142. DOI: 10.3389/fonc.2019.00142.
 13. Selinger C, Bershteyn A, Dimitrov D, **Adamson B**, Revill P, Hallett T, Phillips A, Bekker LG, Rees H, Gray G, and the P5 Global Access Committee. Targeting and Vaccine Durability Are Key for Population-level Impact and the Cost-Effectiveness of a Pox-Protein HIV Vaccine Regimen in South Africa. *Vaccine*. Volume 37, Issue 16, 10 April 2019, Pages 2258-2267. <https://doi.org/10.1016/j.vaccine.2019.02.073>.
 14. Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, **Adamson BJS**, Gross CP, Meropol NJ, Mamtani R. Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life. *The Oncologist*. 2019;24:1-3. DOI: 10.1634/theoncologist.2019-0039.
 15. **Adamson B**, Lipira L, Katz A. The Impact of ACA and Medicaid Expansion on Progress Toward UNAIDS 90-90-90 Goals. *Current HIV/AIDS Reports*. Feb 2019, Volume 16, Issue 1, pp 105-112. DOI: 10.1007/s11904-019-00429-6. <https://link.springer.com/article/10.1007/s11904-019-00429-6>
 16. **Adamson B**, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson J, Garrison L, Donnell D. The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. *Value in Health*, 22 (2019) 194e202. <https://doi.org/10.1016/j.jval.2018.09.001>.
 17. de Montigny S, **Adamson B**, Masse B, Garrison L, Kublin J, Gilbert P, Dimitrov D. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. *Nature Scientific Reports*. 2018 Apr; 8(6066):1-12. DOI:10.1038/s41598-018-24268-4.
 18. Zimmermann M, **Adamson B**, Lam-Hine T, Rennie T, Stergachis A. Assessment Tool for Establishing Local Pharmaceutical Manufacturing in Low- and Middle-Income Countries. *International Journal of Pharmacy Practice*. In Press, 2018.
 19. **Adamson B**, Carlson J, Kublin J, Garrison L. The Potential Cost-Effectiveness of Pre-exposure Prophylaxis Combined with HIV Vaccines in the United States. *Vaccines* 2017, 5(2), 13; doi:10.3390/vaccines5020013
 20. **Adamson B**, Dimitrov D, Devine B, Barnabas R. The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review. *Pharmacoeconomics Open*. 2017 Mar;1(1):1-12. doi: 10.1007/s41669-016-0009-9. Epub 2017 Jan 30.
- Highlight:* Several types of models predict HIV vaccines cost effective. *PharmacoEcon Outcomes News* (2017) 771: 29. doi:10.1007/s40274-017-3740-2

21. **Adamson B**, Fuchs J, Sopher C, Flood D, Johnson RP, Haynes B, Kublin J. A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines. *Clinical and Translational Science*. 2015 Apr;8(2):166-8. doi: 10.1111/cts.12249
22. Sopher CJ, **Adamson BJ**, Andrasik MP, Flood DM, Wakefield SF, Stoff DM, Cook RC, Kublin JG, Fuchs JD. Enhancing Diversity in the Public Health Research Workforce: the Research and Mentorship Program (RAMP) for Future HIV Vaccine Scientists. *Am J Public Health*. 2015 April; 105(4): 823–830. doi: 10.2105/AJPH.2014.302076 Epub 2014 Dec 30.

PUBLISHED | OTHER ARTICLES

1. **Adamson B**, Kraut J, Bennette C. A Health Economist Walks Into a Tech Company: Principles for Reproducible Real-World Analyses. *Value & Outcomes Spotlight*. May/June 2019;5(2):25-26.
2. O'Brien G, Mulcahy M, Byrne S, Carroll D, Courtney G, Walshe V, **Adamson B**. Biosimilar Adoption and Acceptance in Ireland—Still More to Be Done. *Value & Outcomes Spotlight*. 2018 Jul; 4(4):29-31.
3. Gorry C, Akram A, Fayyaz F, Patel J, Adamson B, John J, Szweczyk Z. By the Numbers: The Patient's Voice in Health Care. *Value & Outcomes Spotlight*. 2018 May; 4(3):22.
4. Patel J, Rai P, Suh K, Adamson B. By the Numbers: Milestones in Innovation. *Value & Outcomes Spotlight*. 2018 March; 4(2):20
5. Strand L, **Adamson B**, Delaney J, Basu A. The Good, the Bad, and the Ugly: Reminders About Propensity Scores. *Value & Outcomes Spotlight*. 2017 Nov;3(5):21-22.
6. Chen C, Chou YT, Gangan N, Cannon-Dang E, Lyons N, Law E, **Adamson B**. Trends in Student Interests from 2011-2016: A Report from the ISPOR Survey and Evaluation Committee. *Value & Outcomes Spotlight*. 2017 Sep;3(5):Epub ahead of print.
7. **Adamson B**. Engaging Students and Developing Leaders. *Value & Outcomes Spotlight*. 2017 Jul;3(4):19-20.
8. Shah S, Hastings T, **Adamson B**. Roundtable Discussions: A Framework for Efficient Transfer of Expert Opinions. *Value and Outcomes Spotlight*. 2017 Jul;3(4):21-22.
9. Bounthavong M, **Adamson B**, Basu A. Instrumental Variables: A Tool to Reduce Bias in Non-Randomized Studies. *Value and Outcomes Spotlight*. 2016 Feb;2(1) 24-25.

PUBLISHED | ABSTRACTS

1. Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, **Adamson BJ**, Shaw P, Parikh RB, Mamtani R, Gross CP. The Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. American Society of Clinical Oncology, 2020 Annual Meeting. Poster presentation.
2. Doroshov D, Wei W, Gupta S, Zugazagoitia J, Robbins C, **Adamson BJS**, Rimm D. PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous NSCLC. American Society of Clinical Oncology, 2020 Annual Meeting. Poster presentation.
3. Blakely LJ, Gordon L, Schwartzberg L, Gutman J, **Adamson BJ**, Bourla AB, Meropol NJ, Ramsey SD, Green RJ. Use of Real World Data to Understand Barriers to Interventional Clinical Trial Enrollment in Community Oncology Clinics. American Society of Clinical Oncology, 2020 Annual Meeting. Poster presentation.
4. Wang W, **Adamson B**, Tan K, Baxi S, Briggs A, Ramsey S. Evaluating Long-Term Survival From Clinical Trials: Does Real-World Evidence Change the Paradigm? Health Technology Assessment International (HTAi) 2020, Beijing virtual. Oral presentation.
5. Maignan K, Peleg-Azzam S, **Adamson B**, Parrinello C. Cell of Origin Association with High Body Mass Index and Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. *Blood* (2019) 134 (Supplement_1): 4123. <https://doi.org/10.1182/blood-2019-129470>
6. Kerrigan K, Haaland B, **Adamson B**, Patel S, Akerley W. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers. IASLC 2019 World Conference on Lung Cancer. 8 Sept 2019, Barcelona. Oral Podium Presentation.
7. Kerrigan K, Haaland B, **Adamson B**, Patel S, Akerley W. Real World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer. IASLC 2019 World Conference on Lung Cancer. 8 Sept 2019, Barcelona. Poster Presentation.

8. Bennette C, Segal B, Miksad R, Bellomo L, Nussbaum N, Sarkar S, Tucker T, Abernathy A, **Adamson B**. Building Control Arms For Cancer Clinical Trials From Real-World Data. HTAi 2019 Annual Meeting. 18 June 2019, Cologne.
9. **Adamson BJS**, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ. ACA and Medicaid Expansion Impact on Racial Disparity in Time to Cancer Treatment. *Journal of Clinical Oncology* 37(no. 18_suppl). DOI: 10.1200/JCO.2019.37.18_suppl.LBA1. [ASCO Oral Plenary Session Presentation].
10. Castellanos E, Hamrick J, Ma X, O'Connell G, Orlando A, Meropol N, **Adamson B**. Impact of Oncology Care Model (OCM) reporting requirements on quality of care. *Journal of Clinical Oncology*. 20 May 2019. 37(no. 15_suppl):6620-6620. DOI: 10.1200/JCO.2019.37.15_suppl.6620
11. Feld E, Harton J, Meropol NJ, **Adamson BJS**, Parikh R, Cohen A, Narayan V, Christodouleas JP, Vaughn DJ, Hubbard RA, Mamtani R. Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma. *Journal of Clinical Oncology*. 26 May 2019. 37(no. 15_suppl):e16003-e16003. DOI: 10.1200/JCO.2019.37.15_suppl.e16003.
12. Hooley I, Cohen A, Gross G, Williams E, **Adamson B**. Medicaid Expansion and Racial Inequities in Next Generation Sequencing Testing in Oncology. *Value in Health*. May 2019, Volume 22, Supplement 2, Page S93. DOI: <https://doi.org/10.1016/j.jval.2019.04.322>
13. Hooley I, Chen R, Long L, Cohen A, **Adamson B**. Optimization of Natural Language Processing-Supported Comorbidity Classification Algorithms in Electronic Health Records. *Value in Health*. May 2019, Vol. 22, Supplement 2, Page S87. DOI: <https://doi.org/10.1016/j.jval.2019.04.290>.
14. Ambwani G, Cohen A, Estévez M, Singh N, **Adamson B**, Nussbaum NC, Birnbaum B. Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records. *Value in Health*. May 2019, Vol. 22, Supplement 2, Page S334. DOI: <https://doi.org/10.1016/j.jval.2019.04.1631>.
15. Parikh R, Galsky M, Gyawali B, Riaz F, Kaumann T, Cohen A, **Adamson B**, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. *Journal of Clinical Oncology* 37, no. 7_suppl (March 1 2019) 395-395. DOI: 10.1200/JCO.2019.37.7_suppl.395.
16. Parikh R, Galsky M, Baxi S, **Adamson B**, Cohen A, Feld E, Christodouleas J, Boursi SB, Meropol NJ, Mamtani R. Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma. *Journal of Clinical Oncology* 37, no. 7_suppl (March 1 2019) 392-392. DOI: 10.1200/JCO.2019.37.7_suppl.392.
17. Sam E, **Adamson B**, Garrison L. Discordant Designations of Breakthrough Drug Innovation: France versus the United States. ISPOR Europe Annual Meeting. *Podium Presentation*. Barcelona; 12 Nov 2018.
18. Ulrich A, **Adamson B**, Dimitrov D, De la Grecca R, Wood D, Saldarriaga E, Bansal R, Babigumira J, Cabello R, Sanchez H, Lama J, Duerr A. SABES: A Cost-Effective TasP Intervention to Identify and Treat Recent HIV Infection. Conference on Retroviruses and Opportunistic Infections (CROI). Poster Presentation. Seattle; 4 Mar 2019.
19. **Adamson B**, Dimitrov D, Barnabas R, Kublin J, Carlson J, Garrison L. Potential Competition Between PrEP and HIV Vaccines in Seattle, WA. HIV Research for Prevention Meeting. *AIDS Research and Human Retroviruses*, Vol. 34, No. S1. Poster Presentation. Madrid; 23 Oct 2018.
20. **Adamson B**, Garrison L, El-Sadr W, Donnell D. Incentivizing Adherence with HIV Treatment: Use of Conditional Cash Transfers in Large US Study. American Society of Health Economists Conference. Podium Presentation, Paper 6686. Atlanta; 13 June 2018.
21. Hendrix N, **Adamson B**, Basu A, Devine B. Increasing Trend Toward Reporting Significant Digits in Utility Weights – Behavior Implications of “Flat-of-the-Curve” Medicine? International Society of Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting. *Value in Health*. 2018; 21(1): S208-S109. Baltimore; May 22, 2018. *Research Poster Presentation Award Finalist*.
22. De Montigny S, **Adamson B**, Masse B, Kublin J, Gilbert P, Dimitrov D. How will ART progress affect the impact of future HIV vaccination in South Africa? 27th Annual Canadian Conference on HIV/AIDS Research (CAHR 2018). Poster Presentation. Vancouver, BC; April 26.
23. **Adamson B**, de Montigny S, Masse B, Garrison L, Kublin J, Gilbert P, Dimitrov D. Designing HIV Vaccine Delivery Strategies in South Africa: A Policy Analysis. Conference on Retroviruses and Opportunistic Infections. Poster Presentation. Boston; March 7, 2018.
24. **Adamson B**, Radich J, Bansal A. An Approach for Developing Agent-Based Microsimulation Models that Incorporate Longitudinal Biomarker Trajectories and Dynamic Decision-Making. Society for Medical Decision Making Annual Meeting. Podium Presentation. Pittsburgh; Oct 2017.

BLYTHE ADAMSON, PHD, MPH

25. **Adamson B**, Radich J, Bansal A. Dynamic Decision-Making with Agent-Based Microsimulation Model and Longitudinal Biomarker Trajectories. Western Pharmacoeconomics Conference. Podium Presentation. Albuquerque; Oct 2017.
26. **Adamson B**. "Incentivizing Drug Adherence: Conditional Cash Transfers for HIV Patients." Lindau Nobel Laureate Meeting. Podium Presentation. Lindau, Germany; August 22, 2017.
27. **Adamson B**, Lyons N, Chou YT, Gangan N, Cannon-Dang E, Chen C, Law EH. Meaningful Mentorship Associated with Rewarding Short-Term Research Results from an Evaluation of ISPOR Student Experiences. Poster Presentation. International Society of Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting. Boston; May 2017.
28. Gangan N, Chou YT, **Adamson B**, Cannon-Dang E, Chen C, Law EH, Lyons N. Assessing Trends of Developing Student Interests Within the ISPOR Student Network: 2011 to 2016. Poster Presentation. International Society of Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting. Boston, May 2017.
29. **Adamson B**, Donnell D, Dimitrov D, Garrison G, Beauchamp G, Gamble T, El-Sadr W. The Cost-Effectiveness of Financial Incentives for Viral Suppression in HPTN 065. Conference on Retroviruses and Opportunistic Infections (CROI). Poster Presentation. Seattle, Feb 2017.
30. **Adamson B**, Jain R, Garrison L, Lutz B. Smartphone-Enhanced Rapid Influenza Tests: A Cost-Effectiveness Analysis. *Value in Health*, Vol. 19, Issue 3, A302, May 2016. *Best Poster Finalist*.
31. **Adamson B**, Bouthavong M, Kublin J, Garrison L. Cost-Effectiveness Analysis of a Partially Effective HIV Vaccine in San Francisco. *Value in Health*, Vol. 18, Issue 3, A237, May 2015.
32. Mann M, **Adamson B**, Stergachis, A. A Framework for Strengthening Pharmaceutical Manufacturing in Sub-Saharan Africa. *Value in Health*, Vol. 18, Issue 3, A76. May 2015.
33. **Adamson B**, Bouthavong M, Kublin J, Garrison L. Cost-Effectiveness Analysis of a Partially Effective HIV Vaccine in San Francisco." Western Pharmacoeconomics and Outcomes Research Conference, Poster Presentation, Denver, 2015.
34. **Adamson B**, Hertz T, Duerr A, Morgan C, Keefer M, Churchyard G, Graham B, Gilbert P, Kublin J. Predictors of Immunogenicity in HVTN 204. *AIDS Vaccine*. Poster Presentation, Barcelona, 2013.
35. **Adamson B**, Fuchs J, Sopher C, Flood D, Johnson RP, Haynes B, Kublin J. Development of an Early Stage Investigator Scholar Program for Preclinical Investigators. *AIDS Vaccine*. Poster presentation, Barcelona, 2013
36. **Adamson B**, Wakefield S, Flood D, Stoff D, Sopher C, Cook R, Pemberton N, Kublin J, Fuchs J. HVTN Mentored Research Program for Black and Latino/a Medical Students Increases Intent to Pursue a Career in HIV/AIDS Vaccine Research. *AIDS Vaccine*. Poster Presentation, Barcelona, 2013.

PATENTS

Orlando A, Rich A, Shaw P, Miksad R, Connolly D, **Adamson B**, Tseng J. Clinical Risk Model. U.S. Provisional Patent Application No. 62/990,933 (2020).

Hooley I, Chen R, Longa L, Cohen A, **Adamson B**, Williams E, Ambwani G, Estevez M, Singh N, Nussbaum N, Birnbaum B. Optimizing Natural Language Processing, Sequence Testing, and Biomarker Identification in Health Records. U.S. Provisional Patent Application. Reference No. 13935.6011 (2019).

Lutz B, Jain R. **Adamson B**. "Connected System for Information-Enhanced Test Results," U.S. Provisional Patent Application No. 62/422,506 (2016). Application No. 62/588,099 (2018).

INVITED PRESENTATIONS

1. "Get a job: hunt, decide, and negotiate." Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington. March 7, 2019.
2. "Transforming electronic health records into real world evidence." Clinical and Business Analytics, Stanford Health Care. Sept 19, 2018.
3. Panelist, Student Forum. ISPOR International Annual Meeting. Boston, MA, May 22, 2017.
4. "The Cost-Effectiveness of Financial Incentives for Viral Suppression." HIV Prevention Trials Network Annual Meeting, Statistical Plenary Session. Washington, D.C., Apr 11, 2017.

BLYTHE ADAMSON, PHD, MPH

5. "The War on Drug Prices." Community Conversation Series. Northwest Association for Biomedical Research. Mar 22, 2017.
6. "The Cost-Effectiveness of Financial Incentives for Viral Suppression." Centers for Comparative and Health Systems Effectiveness, Works-In-Progress Seminar Series. University of Washington, Seattle, Feb 27, 2017.
7. "The Potential Cost-Effectiveness of HIV Vaccines in the United States." Corporate Advisory Board Meeting. Department of Pharmacy, University of Washington. Seattle, WA, Sept 15, 2016.
8. "Economics of HIV Vaccines and PrEP" Virology and Infectious Diseases Division Seminar Series. Fred Hutchinson Cancer Research Center, Seattle, Apr 5, 2016.
9. "Economics of HIV Vaccines and PrEP" Pharmaceutical Outcomes Research and Policy Program Seminar. University of Washington, Seattle, WA, Mar 28, 2016.
10. Health Economics Seminar Series. "Economic Value of HIV Vaccines and PrEP" Institute for Disease Modeling, Bellevue, WA, Mar 9, 2016.

TEACHING | LECTURES & WORKSHOPS

Short-Course Instructor: "Tools for Reproducible Real-World Data Analysis." ISPOR International Annual Meeting, New Orleans, 19 May 2019, and ISPOR Europe, Barcelona, 10 Nov 2018.

Workshop: "Generating External Control Arms Using Real-World Data: Analytic Challenges and Recommendations." ISPOR International Meeting. May 2019, New Orleans. Led with Carrie Bennette and Anirban Basu.

HECON 500 Health Economics, Teaching Assistant, University of Washington, Fall 2017.

HECON 520 Economic Evaluation, Teaching Assistant, University of Washington, Winter 2018.

HECON 540 Health Technology Assessment, Teaching Assistant, University of Washington, Spring 2018.

Tuoru College of Pharmacy. "Cost-Effectiveness of HIV Pre-Exposure Prophylaxis." New York, NY, Jan 29, 2018.

BIOENGINEERING 598 Economics and Value in Global Health Technology, Guest Lecturer, University of Washington, Seattle, WA, April 2017, May 2017, May 2018.

Health Economics Impact Study Team (HEIST) Costing Workshop, Lecturer. "Defining U.S. Healthcare Costs for Economic Evaluation." Center for AIDS Research (CFAR), Seattle, WA, April 20, 2017.

Advanced Pharmacology Course. "Pharmacoeconomics in Infectious Diseases" Guest Lecturer, Lakeside Academy, Seattle, WA, Feb 2016 and May 2015.

HONORS | AWARDS

Top 30 Leaders Transforming the Future of Healthcare 08.2019

Business insider list featured in a series of three Business Insider magazine articles

Outstanding Leadership Award 06.2018

University of Washington School of Pharmacy for excellence in graduate student leadership

DLA Best Idea with Global Reach Prize 05.2018

Recognized for a business plan to commercialize novel diagnostic test to fight drug-resistant pathogens

US Delegate to the 6th Lindau Nobel Laureate Meeting on Economics 08.2017

Invited speaker, meeting with 19 Nobel prize winners in Economic Sciences; sponsored by NSF

ISPOR Outstanding Service Award 2017 & 2018

International Society for Pharmacoeconomics and Outcomes Research International Meeting in Boston

Davis Wright Tremaine Most Innovative Award 01.2017

Buerk Center for Entrepreneurship Science and Technology Showcase, for SmartDx ID platform

Health Innovation Challenge Prototype Funding 12.2016

Buerk Center for Entrepreneurship award for development of rapid infectious disease diagnostic platform

BLYTHE ADAMSON, PHD, MPH

Global Innovation eXchange (GIX) Competition Finalist "Smart Diagnostics" prototype awarded 3 rd place in final round of competition in Beijing, China	11.2016
Pre-Doctoral Fellowship in Pharmaceutical Sciences American Foundation for Pharmaceutical Education	09.16 – 08.18
Student Technology Finalist Prize Massachusetts General Hospital Ambulatory Practice of the Future, Gelfand Family Charitable Trust	05.2016
University of Washington Husky 100 Award Captured the Husky Experience and academic pillars, one of 100 among 43,000 students	03.2016
AHRQ T32 Pre-Doctoral Fellowship Agency for Healthcare Research and Quality (AHRQ)	09.14 – 08.16
Reducing Barriers for the Ambitious Scholarship Dr. Dana Hurley Fund, University of Washington School of Pharmacy	2015 & 2016
NIH Center for AIDS Research (CFAR) Trainee Award Summer Institute in Statistics and Mathematical Modeling of Infectious Diseases	07.2015

TECHNICAL | SKILLS

Coding	R, Python, Stata, C++, SAS, VBA, JSON, Stella, WinBugs, LaTeX
Methods	Markov Modeling, Comparative-Effectiveness Analysis, Patient-Level Simulation, Dynamic Transmission, Probabilistic Sensitivity Analysis, Value of Information,

PROFESSIONAL | MEMBERSHIP

International Society of Pharmacoeconomics and Outcomes Research (since 2014)
American Society of Health Economics (since 2017)
HTAi (since 2019)
Academy Health (since 2014)
Academy of Managed Care Pharmacy Student Chapter (since 2015)
Society for Medical Decision Making (since 2016)
Society for Epidemiologic Research (since 2017)

PROFESSIONAL | DEVELOPMENT

CoMotion Innovation Workshop Series Securing intellectual property for technology innovation and commercialization plan for SmartDx platform	01 – 02.2017
Biomedical Research Integrity Series To define and build scientific integrity	06 – 08.2015
Summer Institute in Statistics and Mathematical Modeling of Infectious Diseases Stochastic Epidemic Models with Inference, MCMC for Infectious Diseases, Spatial Statistics Epidemiology	07.2015
Cost Effectiveness Methods in HIV Research NIH Center for AIDS Research (CFAR) workshop	2015
Math Modeling HIV Network Epidemics University of Washington workshop led by Drs. Morris and Goodreau on EPIMODEL programmed in R	07.2013

COMMUNITY | ENGAGEMENT

Facilitator, Community Conversations Series Town hall event "The War on Drug Prices" sponsored by the Northwest Association for Biomedical Research	04.2017
---	---------

BLYTHE ADAMSON, PHD, MPH

Expert Mentor and Speaker

Panelist, speaker, mentor motivating careers in science, math, and global health at Roosevelt High School, Hazel Wolf K-8, Fairview Christian, Nathan Hale High School, and Lakeside Academy

2014 – 2017

Volunteer Elementary Math Instructor

Math workshop instructor building number fundamentals based on the Singapore method at local Seattle public school Hazel Wolf K-8

2015 – 2016

Volunteer Health Care Service in Lilongwe, Malawi

Vaccinated infants and assisted microbiology laboratory malaria and TB diagnostics

2005 & 2008